Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioXcel Therapeutics, Inc. - Common Stock (NQ:BTAI)

2.020 -0.050 (-2.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioXcel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Friday's session: top gainers and losers
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
Get insights into the top gainers and losers of Friday's pre-market session.
Discover the top movers in Friday's pre-market session and stay informed about market dynamics. 
Via Chartmill
Which stocks are experiencing notable movement on Monday?
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
What's Next: BioXcel Therapeutics's Earnings Preview
 
Via Benzinga
BioXcel Therapeutics's Earnings Outlook
 
Via Benzinga
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
The market is filled with gapping stocks in Monday's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
Wondering what's happening in today's after-hours session?
The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
Which stocks are moving on Thursday?
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Thursday's session: top gainers and losers
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Thursday's session: gap up and gap down stocks
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
What's going on in today's after hours session
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
Why Twilio Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
The Next Wave of Health AI: Analysts Highlight Breakthroughs in Clinical Trials and Patient Care
USA News Group Commentary Issued on behalf of Avant Technologies Inc. Vancouver, BC – December 17, 2024 – USA News Group News Commentary – Artificial intelligence (AI) is on the brink of becoming a... 
Via FinancialNewsMedia
Topics Artificial Intelligence
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
BTAI Stock Earnings: BioXcel Therapeutics Beats EPS, Beats Revenue for Q2 2024
BTAI stock results show that BioXcel Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
BioXcel Therapeutics' Approved Drug For Bipolar Disorders/Schizophrenia Shows No Evidence Of Worsening Or Withdrawal In Post-Marketing Study
BioXcel Therapeutics shares topline results from an Igalmi (dexmedetomidine) sublingual film study. The 180 mcg dose demonstrated favorable safety and efficacy in reducing agitation symptoms. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out on Tuesday as we get into all of the hottest news worth reading about this morning! 
Via InvestorPlace
Earnings Scheduled For November 14, 2024
 
Via Benzinga
BTAI Stock Earnings: BioXcel Therapeutics Misses EPS, Beats Revenue for Q1 2024
BTAI stock results show that BioXcel Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
AI Surge Has Ended: All 7 AI Stock Categories Declined This Week
From no AI category losses in February, to 3 drops in March - now all 7 fell this week, clearly indicating that that the surge in AI stock prices that began back on October 31st is, indeed, over. 
Via Talk Markets
Topics Artificial Intelligence
Six Of Seven AI Stock Categories Increased This Week
All but one of the 7 artificial intelligence stock categories that I analyze weekly increased in value this week. But two categories are still down MTD, suggesting that the surge in the artificial... 
Via Talk Markets
Topics Artificial Intelligence
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
Bullish speculators could have their opportunity to blow up the bears with these short-squeeze stocks to buy. 
Via InvestorPlace
Earnings Scheduled For March 12, 2024
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter. 
Via Benzinga
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
Grand View Research says the global 
Via Talk Markets
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway. 
Via Talk Markets
Topics Artificial Intelligence
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
From FN Media Group LLC
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.